Small Molecules

19 Dec 2018 FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
19 Dec 2018 Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial
19 Dec 2018 Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
19 Dec 2018 Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
19 Dec 2018 Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update
19 Dec 2018 Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150
19 Dec 2018 Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis
19 Dec 2018 Lexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211
19 Dec 2018 Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective
17 Dec 2018 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
17 Dec 2018 Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17 Dec 2018 DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease
14 Dec 2018 NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression
14 Dec 2018 Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
14 Dec 2018 CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
14 Dec 2018 Sosei Heptares Starts New Clinical Development Program - First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders
14 Dec 2018 Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
14 Dec 2018 Sensorion Announces Positive Topline Results From Seliforant Phase 2a Study
12 Dec 2018 Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
11 Dec 2018 Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
11 Dec 2018 Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
11 Dec 2018 Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11 Dec 2018 MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11 Dec 2018 Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
11 Dec 2018 Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b Clinical Trial in Refractory Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up